Analysis of Recorded Morbidity, Prevalence and Hospital Mortality of Patients with Symptomatic Multiple Myeloma in the Ryazan Region for 10 Years

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

INTRODUCTION: Multiple myeloma (MM) is a disease whose substrate is plasma cells; it is characterized by the production of monoclonal immunoglobulin. Epidemiology of MM in Russia is insufficiently studied. Of interest is a study of dynamics of the main epidemiological parameters of multiple myeloma in the context of a poor epidemiological prognosis for oncological diseases in the Russian Federation and in the world in general.

AIM: To analyze the main epidemiological parameters of symptomatic MM in the Ryazan region for 10 years (2010–2019).

MATERIALS AND METHODS: A total of 343 medical records of patients with symptomatic MM were analyzed, of them 146 men (age median — 65 years), 197 women (age median — 64 years). The patients underwent inpatient treatment in the hematology and chemotherapy department of Ryazan Regional Clinical Hospital from 2010 to 2019. The epidemiological analysis consisted in evaluation of the parameters of the registered morbidity, prevalence and hospital mortality. The criterion for inclusion in the study was the existence of symptomatic MM in the patient. For statistical processing, Microsoft information and analytical system, Office package was used.

RESULTS: The highest amount of new cases of MM were identified in 2018 (4.19 per 100,000 population), the lowest — in 2012 (1.83 per 100,000 population). In the analyzed period, the number of cases of newly diagnosed MM per year increased by 30.3%. Most patients at the time of diagnosis were in the age group of 60−69 years. Morbidity with MM in the age group of 30−49 years was comparable in men and women, however, among the patients ≥ 50 years women predominated. Over 10 years, the index of MM prevalence in the Ryazan region increased 1.43 times: from 6.71 to 9.6 per 100,000 population, index of hospital mortality — from 1.4% to 3.3%.

CONCLUSION: The growth of the registered mortality and prevalence of MM in the Ryazan region in 2010−2019 was identified, which corresponds to the dynamics in other regions of the Russian Federation. Also, during the analyzed period, an increase in hospital mortality of patients with MM was observed in the region.

Full Text

Restricted Access

About the authors

Sergey G. Bolotin

Ryazan Regional Clinical Hospital

Email: s.bolotin5@gmail.com
ORCID iD: 0000-0002-9930-1588
SPIN-code: 2557-0443
ResearcherId: CAG-0464-2022
Russian Federation, Ryazan

Mariya S. Zenina

Ryazan State Medical University

Email: zeninamm@mail.ru
ORCID iD: 0000-0003-1566-6123
SPIN-code: 5025-1494
ResearcherId: CAG-1947-2022
Russian Federation, Ryazan

Aleksandra V. Solov’yeva

Ryazan State Medical University

Email: savva2005@bk.ru
ORCID iD: 0000-0001-7896-6356
SPIN-code: 1943-7765
ResearcherId: U-9328-2018

MD, Dr. Sci. (Med.), Associate Professor

Russian Federation, Ryazan

Alexandr S. Pristupa

Ryazan Regional Clinical Hospital; Ryazan State Medical University

Author for correspondence.
Email: alpristupa@mail.ru
ORCID iD: 0000-0001-6842-5660
SPIN-code: 4067-7270
ResearcherId: CAJ-2028-2022

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, Ryazan, Ryazan

References

  1. Mnozhestvennaya miyeloma. Klinicheskiye rekomendatsii. Moscow; 2020. Available at: https://cr.minzdrav.gov.ru/schema/144_1. Accessed: 2022 September 14. (In Russ).
  2. Skvortsova NV, Kovynev IB, Khalzov KV, et al. Comorbidity and Personalized Treatment of Multiple Myeloma in Real Clinical Practice. Clinical Oncohematology. 2020;13(3):322–34. (In Russ). doi: 10.21320/2500-2139-2020-13-3-322-334
  3. Davydkin IL, Shpigel’ AS, Mordvinova EV, еt al. Quality of life of patients with lymphoproliferative diseases. Astrakhan Medical Journal. 2021;16(2):6–18. (In Russ). doi: 10.17021/2021.16.2.6.18
  4. Luchinin AS, Semochkin SV, Minaeva NV, et al. Epidemiology of multiple myeloma according to the Kirov region population registers. Oncohematology. 2017;12(3):50–6. (In Russ). doi: 10.17650/1818 8346-2017-12-3-50-56
  5. Ludwig H, Novis Durie S, Meckl A, et al. Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment. The Oncologist. 2020;25(9):e1406–13. doi: 10.1634/theoncologist.2020-0141
  6. Skvortsova NV, Pospelova TI, Kovynev IB, et al. Epidemiology of Multiple Myeloma in Novosibirsk (Siberian Federal District). Clinical Oncohematology. 2019;12(1):86–94. (In Russ). doi: 10.21320/2500-2139-2019-12-1-86-94
  7. Vinogradova OY, Ptushkin VV, Chernikov MV, et al. Epidemiology of multiple myeloma in city Moscow. Therapeutic Archive. 2019;91(7):83–92. (In Russ). doi: 10.26442/00403660.2019.07.000305
  8. Pogadaeva MS, Setko IA, Yarnyh AV. Epidemiology of Multiple Myeloma of the Orenburg region. Abstracts Nationwide scientific forum of students with international participation «Student science — 2020. Forcipe. 2020;3(S1):161–2. (In Russ).
  9. Zvereva ON. Mnozhestvennaya miyeloma u naseleniya Arkhangel’ska. Gematologiya i Transfuziologiya. 2012;57(3, Suppl):110–1. (In Russ).
  10. Pivnik AV, Vorob’yeva TV, Volodicheva EM. Analiz zabolevayemosti mnozhestvennoy miyelomoy v Tul’skoy oblasti. Problemy Gematologii i Perelivaniya Krovi. 2000;(4):31–4. (In Russ).
  11. Bolotin SG, Zenina MS, Pristupa AS, et al. Clinical and epidemiological characteristics of multiple myeloma in the Ryazan region. Nauka Molodykh (Eruditio Juvenium). 2020;8(4):541–8. (In Russ). doi: 10.23888/HMJ202084541-548
  12. Butukhanova IS, Zhalsanova EB, Alekseeva AN, et al. The analysis of the multiple myeloma morbidity in Buryatia republic. Modern Problems of Science and Education. 2016;(4). Available at: https://science-education.ru/ru/article/view?id=24818. Accessed: 2022 September 14. (In Russ).
  13. Population and Census Data. Available at: https://eng.rosstat.gov.ru/folder/11654. Accessed: 2022 September 14. (In Russ).

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Age structure of cohort of patients with newly diagnosed multiple myeloma in the Ryazan Region in 2011–2019.

Download (36KB)
3. Fig. 2. Recorded morbidity with multiple myeloma in the Ryazan Region from 2011 to 2019 per 100 thousand population (in parenthesis the absolute number of patients is given).

Download (86KB)
4. Fig. 3. Parameter of prevalence of multiple myeloma in the Ryazan Region from 2010 to 2019 per 100 thousand population (in parenthesis the absolute number of patients is given).

Download (77KB)
5. Fig. 4. Dynamics of hospital mortality of patients with multiple myeloma in the Ryazan Region from 2010 to 2019 (in parenthesis, the percentage from the number of hospitalizations is given).

Download (80KB)

Copyright (c) 2022 Eco-Vector


Media Registry Entry of the Federal Service for Supervision of Communications, Information Technology and Mass Communications (Roskomnadzor) PI No. FS77-76803 dated September 24, 2019.



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies